Last edition
News about "Sun Pharmaceutical"
Sun Pharmaceutical’s partner Philogen, a Swiss-Italian biotechnology company, has provided an update on the Phase III FIBROSARC trial evaluating Fibromun (L19TNF) in combination with doxorubicin versus doxorubicin alone as first-line treatment for patients with advanced or metastatic Soft Tissue Sarcoma (STS).
Sun Pharmaceutical | 12/11/2025 | By Dineshwori
Philogen Completes Patient Enrollment of Phase III FIBROSARC Trial in STS
All ongoing Fibromun trials remain on track with their expected timelines.
Sun Pharmaceutical | 05/02/2025 | By Aishwarya | 908
Sun Pharma Signs Global Exclusive Deal with Philogen for Commercializing FIBROMUN
Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.
Sun Pharmaceutical | 01/10/2024 | By Aishwarya | 395
EMA Approves Marketing Authorization Application of Nidlegy
Philogen and Sun Pharmaceutical Industries Ltd. have announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy.
Sun Pharmaceutical | 05/07/2024 | By Aishwarya | 346
Sun Pharma Announces Complete Acquisition of Taro
Sun Pharmaceutical Industries Ltd. has completed the merger of Taro Pharmaceutical Industries Ltd. with its subsidiary.
Sun Pharmaceutical | 25/06/2024 | By Aishwarya | 493
Sun Pharma Launches SEZABY in US to treat neonatal seizures
This is the first and only FDA Approved product in US to treat neonatal seizures
Sun Pharmaceutical | 27/01/2023 | By Sudeep Soparkar | 973
Sun Pharma receives US FDA communication as OAI
The communication states that the US FDA may withhold approval of any pending product applications or supplements filed from this facility<br />
Sun Pharmaceutical | 09/11/2022 | By Sudeep Soparkar | 668
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy